Cyclin A2 is predominantly, but not exclusively, localized in the nucleus from G1/S transition onwards. It is degraded when cells enter mitosis after nuclear envelope breakdown. We previously showed that a fusion protein (S2A) between the hepatitis B virus (HBV) surface antigen protein and a non-degradable fragment of human cyclin A2 (D152) resides in the endoplasmic reticulum membranes, escapes degradation and transforms normal rat ®broblasts. The present study investigates whether cytoplasmic cyclin A2 may play a role in oncogenesis. We show that the sequestration of non-degradable cyclin A2-D152 by a cellular ER targeting domain (PRL-A2) leads to cell transformation when coexpressed with activated Ha-ras. REF52 cells constitutively expressing PRL-A2 are found to have a high incidence of multinucleate giant cells, polyploidy and abnormal centrosome numbers, giving rise to the nucleation of multipolar spindles. Injection of these cells into athymic nude mice causes tumors, even in the absence of a cooperating Ha-ras oncogene. These results demonstrate that, independently of any viral context, an intracellular redistribution of non-degradable cyclin A2 is capable of deregulating the normal cell cycle to the point where it promotes aneuploidy and cancer.
Introduction
Cyclins play an essential role in progression through the eukaryotic cell cycle, acting as regulatory subunits of cyclin-dependent kinases (CDKs). A-and B-type cyclins are more speci®cally responsible for the onset of mitosis, and, through their degradation, the exit from mitosis. Their activities are determined by changes in their subcellular localization during successive phases of the cell cycle (Pines, 1999) .
Cyclin A2 achieves its regulatory activity predominantly, if not exclusively, in the nucleus, contributing to the S phase and entry into the prophase (Furuno et al., 1999) . However, several reports have described the presence of cyclin A2 within the cytoplasm during the S phase (Carbonaro-Hall et al., 1993; Girard et al., 1991) and within the centrosome during mitosis (Bailly et al., 1992; Winston et al., 2000) . This cytoplasmic fraction of cyclin A2 may play a signi®cant role in cell cycle control. Indeed, it has been shown that cyclin A2 may play a signi®cant role in cell cycle control. Indeed, it has been shown that cyclin A2 kinase acts upon the microtubule nucleating activity of centrosome (Buendia et al., 1992) and endosome fusion (Thomas et al., 1992; Woodman et al., 1993) . Cyclin A-CDK2 complexes have been found in the microsomal and endocytic compartments of regenerating liver cells (Castro et al., 1994; Lu et al., 1992; Verges et al., 1997) . These complexes exhibit histone H1 kinase activity, but their cytoplasmic targets have not been determined.
The present investigation of the role of cytoplasmic cyclin A2 in cell cycle control originated from the prior identi®cation of a mutant cyclin A2 in a human hepatitis B virus (HBV)-induced hepatoma (Wang et al., 1990) . This mutant consists of the PreS2/St portion of HBV fused to the N-terminally truncated cyclin (A2-D152). It is constitutively localized to the endoplasmic reticulum (ER) membranes through its viral portion, the cyclin portion being exposed on the cytoplasmic side of the ER (Berasain et al., 1998) . It is endowed with in vitro and in vivo transforming activity (Berasain et al., 1998) . No transformation has been observed with A2-D152 alone or wild-type cyclin A2. PreS2/St alone transactivated target genes but did not induce any transformation (Berasain et al., 1998; Kekule et al., 1990; Lauer et al., 1992) . This suggests that the stabilization (absence of the Destruction-box, or Dbox) and targeting of cyclin A2 to the ER are responsible for the oncogenic activity of S2A, independently of the viral context. In this case, the retention of cyclin A2 in the ER membrane by any cellular signal peptide should lead to oncogenic activation.
In this study, we used a chimeric protein, called PRL-A2, in which cyclin A2-D152 was fused to a cellular ER targeting domain (PRL) containing the prolactin signal peptide in frame with an IgM stop transfer sequence. The stable expression of PRL-A2 in rat embryo ®broblasts (REF52) resulted in multinucleation, polyploidy and abnormal centrosome duplication, giving rise to the nucleation of multipolar spindles. Injection of these cells into athymic nude mice caused tumors, even in the absence of a cooperating Ha-ras oncogene. These results raise the question of the mechanisms through which an increase of cytoplasmic cyclin A kinase activity generates aneuploidy and genomic instability.
Results

Oncogenic properties of ER-targeted cyclin A2 in REF52 cells
In order to investigate the function of the cytoplasmic cyclin A2 pool we used the chimeric proteins PRL-A2 and S2A, as sketched in Figure 1 . These proteins lack their cyclin A2 destruction boxes and are targeted to the ER membrane, the cyclin A2 portion being on the cytosolic side. The principal dierence between S2A and PRL-A2 is the nature (respectively viral or cellular) of the amino-terminal ER-targeting portion. We have studied the phenotype induced by the ectopic expression of PRL-A2 in REF52 cells. These cells are immortal but, like primary REFs, display a high degree of growth control and require the coexpression of a cooperating oncogene in order to be transformed by ras (Franza et al., 1986) . We transfected REF52 cells with S2A or PRL-A2 expression vectors, either alone or in combination with an activated version of Ha-ras (H-rasV12). Transformed foci were obtained when H-rasV12 was expressed with either PRL-A2, S2A or myc (Table 1) . Similar results were obtained when the transformation assay was performed on primary REFs (data not shown). REF52 cells transfected with S2A or PRL-A2 alone were not transformed, but their morphology was profoundly altered compared with that of parental cells or cells transfected with the vector alone or H-rasV12 and myc constructs (see below). Cells expressing cyclin A2-D152, with or without HrasV12, were not transformed (not shown and (Berasain et al., 1998) ).
We established ®ve independent, transformed clones transfected with both Ha-ras and PRL-A2 expression vectors, and three independent, nontransformed clones transfected with the PRL-A2 vector alone. Parental REF52 cells, clones transformed with H-rasV12 and myc vectors, and clones transfected with the pMC1neo empty vector, were studied in parallel. Ras+PRL-A2 and PRL-A2 stable clones were analysed for PRL-A2 expression and localization. PRL-A2 was expressed at various levels among the clones analysed ( Figure 2 ) and was located in the ER membranes. This was con®rmed by double immunostaining with anti-cyclin A2 and anti-ER antibodies (data not shown). 20% of cells were giant, bi-or multinucleated with deformed nuclei, suggesting that the overexpression of PRL-A2 induces polyploidy (Figure 3 ). By comparison, cells transfected with pMC1neo vector or H-rasV12 and myc constructs exhibited a normal morphology (Figure 3 ).
Selected clones were injected into nude mice, and tumors were scored over a period of 6 months ( Table  2) . Tumors were detected in all animals injected with Ras+PRL-A2 or Ras+Myc clones. Mice injected with PRL-A2 clones also developed tumors, but the process was slower. The immunohistochemical staining of tumors derived from Ras+PRL-A2 clones revealed that the protein that has been used to transform the original cells was expressed in the cytoplasm of giant multinucleated cells (Figure 4 ). It was of note that such giant cells were not observed in transformed Ras+Myc clones. Thus PRL-A2 behaved as an oncogene in the nude mouse, as well as in the cell transformation assay. Position of the MRAIL motif necessary for the interaction of cyclin with CDKs: residues 210 to 214. D-box: (hatched): destruction box. PreS2/St: truncated middle envelope protein of HBV, in which the 55-residue preS2 domain is fused to the 101-residue truncated S domain. Asterisks: the two in-frame methionines of the preS2 and S sequences. Forked symbol: glycosylation site (Asn4 in preS2). Stippled boxes: transmembrane a-helices which determine ER membrane insertion of the S domain (Eble et al., 1987; Prange and Streeck, 1995) . S2A: chimeric protein resulting from integration of the HBV genome into the human cyclin A2 gene. PRL: ER targeting domain containing the signal sequence of bovine prolactin (coarse hatching) fused with an E. coli b-lactamase and a mouse IgM heavy chain stop transfer sequence (®ne hatching). PRL-A2: protein resulting from the fusion of A2-D152 to PRL
Cells expressing PRL-A2 display polyploidy and centrosome amplification
Polyploidy of PRL-A2 expressing cells was established by FACS analysis ( Figure 5 ). At con¯uence, PRL-A2 clones exhibited an enrichment in G2/M cells compared with the Neo clone, which was arrested with a G0/G1 DNA content. The distributions of the DNA content in PRL-A2 and Ras+PRL-A2 clones are broad and show no well-de®ned peaks above 2C, suggesting that these clones are aneuploid. We are currently attempting to quantify the amount of DNA in these cells in order to clarify this point. Twenty to twenty-nine per cent of PRL-A2 cells were polyploid. The expression of PRL-A2 with H-rasV12 also induced polyploidy (in 11 ± 21% of cells). The proportion of G2/M cells was highly variable among the ®ve studied clones (3 ± 52%). The enrichment in G2/M cells and the increase in nuclear DNA content were not correlated with the expression levels of PRL-A2 (Figures 2 and 5) . No polyploid cells were detected in H-rasV12+myc transformed clones.
We next measured the number of centrosomes in the various clones, using a monoclonal antibody raised against polyglutamylated tubulin (GT335), a marker of the centrioles (Figure 6 ). Ten per cent of cells expressing PRL-A2 showed abnormal ®gures of mitosis associated with an increased number of centrioles, which was not related to the number of nuclei. Bi-or tri-nucleated cells were found to contain up to 25 centrioles in a transformed Ras+PRL-A2 clone and up to 11 centrioles in a non-transformed PRL-A2 clone. However, normal mitoses without centrosome ampli®cation were also observed in a signi®cant percentage of cells. Neither multinucleated cells nor multipolar mitoses were observed in the control Neo and Ha-ras+myc clones (not shown). Thus, PRL-A2 expression alone appeared to be responsible for ploidy and mitosis abnormalities.
Discussion
Our study emphasizes the impact of cytoplasmic cyclin A2 localization on cell transformation. It also demonstrates the induction of polyploidy and centrosome ampli®cation by such a cytoplasmic membraneanchored localization.
Evidence has accumulated concerning the role of cyclins D and E in human carcinogenesis (Gudas et al., 1999) . The expression of full-length cyclins D and E, in cooperation with oncogenes such as ras and myc, induced cell transformation in vitro and in vivo (Haas et al., 1997a,b) . On the other hand, there has so far been no evidence for the transforming capacity of fulllength cyclin A2, despite the major role played by this cyclin in the cell-cycle progression. A previous study based on an HBV-cyclin A2 fusion protein suggested a new mechanism of cyclin-related cell transformation, in which an absence of degradation and abnormal cytoplasmic localization, instead of mere accumulation, were the causes of cell transformation (Berasain et al., 1998) . However, these experiments were insucient to completely rule out the possibility that the viral moiety itself contributed to cell transformation, since truncated HBV envelope proteins have been shown to play a role in liver carcinogenesis (Hildt and Hofschneider, 1998) .
We have recently shown that such truncated cyclin A2 recruit and activate cyclin A2 kinase in the vicinity of the ER membrane leading to M-phase entry in Xenopus oocytes. These results indicate that folding of the anchored protein and the biochemical microenvironment existing near the membrane are favorable to the binding, enzymatic activation and cellular function of Cdks (Faivre et al., 2001 ). To understand how these Cdks deregulate the cell cycle it will be necessary to identify the substrates speci®c to cyclin A2 kinase in the cytoplasm.
By testing a truncated cyclin A2 mutant (PRL-A2) devoid of any HBV sequence, the present investigation de®nitively establishes that the localization of cyclin A2 to the ER membrane is sucient to trigger cell transformation. Other recent studies have shown that cyclin A2 may accumulate in the cytoplasm under physiological conditions (Grzanka and Styczynski, 2001 ). Of particular interest are reports of an increase in membrane-associated cytoplasmic cyclin A2 kinase activity during liver cell proliferation following partial hepatectomy (Albrecht et al., 1999; Castro et al., 1994; Lu et al., 1992; Verges et al., 1997) . Furthermore, Nterminally deleted cyclin A2 products were found to exhibit cytoplasmic localization, and have been detected under various conditions, in particular in transformed cell lines (Kaufmann et al., 2001) .
Another noteworthy observation of the present study was that the localization of cyclin A2-D152 at the ER membrane promotes polyploidy and abnormal centrosome numbers in giant cells. This phenotype has not been observed in cells overexpressing full-length or truncated cyclin A2 (D152), the latter being predominantly nuclear (Faivre, unpublished observations; Berasain et al., 1998) ). Cyclin A2-dependent kinase is mainly known to exert its activity in the nucleus, where it accumulates at the G1/S transition (Maridor et al., 1993) , and triggers consecutively S phase entry and progression, DNA replication and entry into mitosis. Cyclin A2 also inhibits the re-replication of origins, through the phosphorylation of CDC6, an essential component in the origin binding complex (Coverley et al., 2000; Petersen et al., 1999) . Recent studies have shown that cyclinA2-Cdk2 plays a role in regulating the anaphase promoting complex (APC), preventing a premature degradation of cyclin B by phosphorylating Cdh1, one of the activator subunits of APC Sorensen et al., 2001) . Along the same lines, there is evidence that cyclin A2 kinase plays a role in centrosome duplication in somatic mammalian cells (Meraldi et al., 1999) . However, whether centrosome duplication is triggered by cytoplasmic or nuclear factors is still a matter of debate (Sluder and Hinchclie, 1999; Sluder et al., 1986) . Our data indicate that constitutive cytoplasmic cyclin A2-kinase activity impinges on cell cycle regulation, without arresting the cell-cycle. In contrast, stabilized versions of cyclin A have resulted in premature S phase entry (Sprenger et al., 1997) and metaphase delay (Jacobs et al., 2001; Parry and O'Farrell, 2001 ) when overexpressed in Drosophila. Similarly, in human Hela cells, the expression of cyclin A mutants lacking the degradation signal arrested cells in the anaphase (Geley et al., 2001) . The hypothesis that ER-anchored cyclin A2 kinase activity may override the mitotic checkpoints or perturb cytokinesis could explain why cyclin A2-expressing REF52 cells exhibit a lengthening in G2/M phase and polyploidy.
Several studies have emphasized the impact of the subcellular distribution of Cdk inhibitors, mainly p21 and p27, on cell cycle regulation (Orend et al., 1998) . There is also evidence for the impact of such subcellular distribution in oncogenesis (Soucek et al., 1998) . Along the same lines, an alteration of the equilibrium between the two cyclin A2 populations (nuclear and cytoplasmic) in favor of the cytoplasmic pool may be responsible for aneuploidy, and hence the tumors in our study. The tumorigenicity of PRL-A2 expressing cells, which shows up after a long delay, may result from gene expression anomalies due to imperfect division. Indeed, the expression of cytoplasmic cyclin A2 was sucient to trigger a series of events, namely centrosome ampli®cation, multipolar mitotic spindle formation, chromosome missegregation and genetic instability, which are frequently observed in many human malignancies (Duensing and Munger, 2001; Lingle and Salisbury, 2000) .
The impact of cyclin A2 accumulation as a prognostic marker in human cancers has been underlined by previous studies (Allan et al., 2000; Brechot, 1993; Handa et al., 1999; Huuhtanen et al., 1999; Zhai et al., 1999) . Most of these investigations did not speci®cally address the cellular distribution of cyclin A2. Importantly, however, some studies have noted the cytoplasmic accumulation of cyclin A2 in tumor cells (Aaltomaa et al., 1999a,b) . Thus, these data, together with our study, suggest that the cytoplasmic distribution of cyclin A2 should be carefully analysed when investigating the expression of cyclin A2 in human cancers.
Materials and methods
Plasmid constructs
The cyclin A2-D152 coding sequence was cloned in plasmid pSp Sp+1.L.ST.gG in frame with the b-lactamase signal sequence and the carboxy-terminal transmembrane sequence of membrane IgM heavy chain (which we call PRL). Lingappa et al. (1984) and Yost et al. (1983) have shown that this sequence causes a complete translocation across the } } } } ER membrane when coupled to cytoplasmic proteins. To achieve expression in mammalian cells, the above construct was subcloned into pOPRSVICAT (Stratagene). Plasmid pMC1neo (Stratagene) and those encoding S2A, Ha-ras and Myc were as described (Berasain et al., 1998) .
Cell culture, formation of foci and tumorigenicity assay Rat embryo ®broblasts (REF 52) were grown at 378C in a 5% CO 2 atmosphere in Dulbecco's modi®ed Eagle Medium glutamax (Life Technologies), supplemented with 10% bovine calf serum, 100 iu/ml penicillin and 100 mg/ml streptomycin. Cells were transfected with 10 mg of each plasmid per 10 cm culture dish using the calcium-phosphate coprecipitation method, and passaged 48 h later to four dishes with either 800 mg/ml G418 (Gibco)-containing or normal medium. After 3 weeks of culture without selection, the cells were ®xed in Carnoy's solution (methanol : chloroform : glacial acetic acid=6 : 3 : 1) and stained with Giemsa. For the tumorigenicity assay, ®ve million cells were injected subcutaneously into each¯ank of nude mice. Tumors were scored over a period of 6 months.
Western blot analysis
Total REF52 protein extracts were prepared in RIPA buer (20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate) containing protease inhibitors. Equal amounts of REF52 extracts were separated on 12% SDS ± PAGE, transferred onto nitrocellulose (Amersham) and processed for immunoblotting, using HRPconjugated secondary antibodies (Jackson Immuno Research) and chemoluminescence (Amersham).
Indirect immunofluorescence
Cells grown on coverslips were ®xed in cold methanol for 6 min at 7208C, rinsed in PBS and then incubated with a primary antibody diluted in PBS containing 3% BSA for 1 h, followed by¯uorescein-conjugated donkey anti-rabbit or anti-mouse antibodies (Jackson ImmunoResearch). DNA was counterstained with 1 mg/ml 4', 6-diamino-2-phenylindole (DAPI)¯uorescent dye (Sigma). Confocal Laser Scanning Microscopy was performed using a Leica confocal imaging system (TCSSP, Leica, Germany) with an oil immersion lens (636, PL Apo). Optical sections were collected at 0.5 mm intervals.
Immunohistochemistry
Formalin-®xed, paran-embedded sections (5 mm) of tumor samples were de-waxed in xylene prior to rehydration. The sections were then microwaved for 10 min at 650 W in 0.01 M citrate buer, pH 6.0. After incubation in TBS (Tris-buered saline, 10 mM Tris-HCl pH 7.6, 150 mM NaCl) with 1% bovine serum albumin for 20 min to block non-speci®c antibody binding, the sections were incubated with the primary antibody for 30 min and then with a biotinylated goat anti-rabbit antibody diluted to 1 : 100 for 30 min (Vector). After washing in TBS, the slides were incubated for 20 min at room temperature with streptavidin-coupled alkaline phosphatase (Dako). The signal was developed with diaminobenzidine containing 0.01% hydrogen peroxide for 10 min, followed by counterstaining with hematoxylin.
Cell cycle analysis
Cells were trypsinized, washed twice with PBS, and ®xed in 70% ethanol. Fixed cells were incubated with 100 mg/ml RNase for 30 min at 378C and stained with propidium iodide (50 mg/ml). 20 000 cells were analysed on a FACScan¯ow cytometer. 
